Skip to main content
$16.18 -$0.07 (-0.4%)

01:14 PM EST on 03/04/24

NovoCure (NASDAQ:NVCR)

CAPS Rating: 4 out of 5

Current Price $16.18 Mkt Cap $1.7B
Open $16.26 P/E Ratio -8.35
Prev. Close $16.25 Div. (Yield) $0.00 (0.0%)
Daily Range $15.88 - $16.28 Volume 233,591
52-Wk Range $10.87 - $83.60 Avg. Daily Vol. 1,342,161

Caps

How do you think NASDAQ:NVCR will perform against the market?

Add Stock to CAPS Watchlist

All Players

416 Outperform
2 Underperform
 

All-Star Players

39 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:NVCR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Foolme21 (< 20)
Submitted March 10, 2022

TTFields have extended overall patient survival for glioblastoma (GBM). Based on successful GBM treatment and research indicating that TTFields can improve treatment for other cancers, Novocure's TAM will greatly expand. Results from the LUNAR… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:NVCR Summary

Fools bullish on NASDAQ:NVCR are also bullish on:

Fools bearish on NASDAQ:NVCR are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about NVCR.

Recs

1
Member Avatar Foolme21 (< 20) Submitted: 3/10/2022 12:20:15 PM : Outperform Start Price: $64.66 NASDAQ:NVCR Score: -97.36

TTFields have extended overall patient survival for glioblastoma (GBM). Based on successful GBM treatment and research indicating that TTFields can improve treatment for other cancers, Novocure's TAM will greatly expand. Results from the LUNAR (non-small cell lung cancer, NSCLC) and INNOVATE-3 (ovarian cancer) phase 3 clinical trials are due later in 2022/2023, respectively. If trials indicate TTFields extend patient survival beyond GBM, then NovoCure will outperform the S&P 500.

Recs

1
Member Avatar Reserved1 (< 20) Submitted: 1/7/2022 10:18:28 AM : Outperform Start Price: $68.92 NASDAQ:NVCR Score: -86.43

Medical research with little to no competition

Recs

1
Member Avatar willieram (< 20) Submitted: 11/22/2021 1:07:53 PM : Outperform Start Price: $97.69 NASDAQ:NVCR Score: -92.52

Fourth method for cancer treatment. Non invasive technology, no side effects, potentially able to treat most tumors. Revolutionary.

Leaderboard

Find the members with the highest scoring picks in NVCR.

Score Leader

oldlumike

oldlumike (37.74) Score: +529.29

The Score Leader is the player with the highest score across all their picks in NVCR.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
TMFSecurity 94.73 11/16/2021 Underperform NS $112.35 -85.68% +9.80% +95.48 0 Comment
PAGEBOY73 93.62 8/28/2023 Underperform 5Y $20.11 -19.97% +16.29% +36.26 0 Comment
aordinaryguy 65.29 1/25/2024 Outperform 1Y $13.73 +17.19% +5.45% +11.74 0 Comment
MoolaMonster 64.65 2/21/2024 Outperform 5Y $15.37 +4.65% +3.45% +1.21 0 Comment
TMFHorst 91.58 10/25/2023 Outperform 5Y $14.09 +14.19% +21.58% -7.38 0 Comment
TMFJoryko 85.52 8/29/2023 Outperform 5Y $20.25 -20.54% +14.21% -34.75 0 Comment
SuperCharge 69.79 8/18/2023 Outperform NS $31.00 -48.10% +18.36% -66.46 0 Comment
BringUs 97.53 7/24/2023 Outperform 5Y $37.92 -57.57% +12.91% -70.47 0 Comment
bignej 60.18 7/3/2023 Outperform NS $41.58 -61.30% +15.74% -77.04 0 Comment
20Fool20 20.62 6/14/2023 Outperform 5Y $45.68 -64.78% +17.29% -82.06 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NVCR.